Arnatar
arnatar.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
201-500
employees, estimated range
Backers
1
F-Prime Capital
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
F-Prime Capital Similar startupsby what they do, their industry and backers
Deliveringon the RNARevolution. At Avidity Biosciences, we are driven by our mission: to profoundly improve people's lives by…
FROM CELLS TO ORGANELLES• ORGANELLES•. First-in-Class Isolated Organelles for Drug Discovery.
Correctors and Potentiators for Autosomal Dominant Polycystic Kidney Disease (ADPKD). Transforming the Treatment of ADPKD.
Kalium Health | Precision testing to transform the management of chronic kidney disease and heart disease.
Somatus is a leader in value-based kidney care working alongside health plans and providers to help prevent the progression of kidney…
Ochre Bio is a London biotechnology company founded in 2019 that develops RNA medicines for chronic liver disease. It tests candidates on…
News
Arnatar Therapeutics Receives China NMPA Clearance to Initiate First-in-Human Study of ART5, a First-in-Class Up-Regulating ASO Designed to Restore Polycystin-1 for the Treatment of ADPKD
ART5 is designed to address the most common root cause of ADPKD by targeting PKD1, potentially restoring PC1 production in approximately 85% of patientsFirst-in-human SAD study in healthy volunteers expected to initiate Q3 2026Phase 1b study in patients w
Read more
Report
Arnatar emerges with RNA approach to both silence and restore
A few years after it was founded with the aim of taking RNA therapies to the next level, Arnatar Therapeutics Inc. emerged from stealth, disclosing a $52 million series A round raised in 2024 as well as U.S. FDA orphan and rare pediatric disease designati
Read more
Report
Arnatar Therapeutics Emerges from Stealth and Announces Receipt of FDA Orphan Drug and Rare Pediatric Disease Designations for ART4
$52M Series A raised in 2024, led by Eight Roads and 3E BioventuresSAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today an
Read more
Report